Eligibility B-Cell Chronic Lymphocytic Leukemia NCT00302861

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
have signed a written informed consent
Description

written informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
b-cll diagnosis
Description

b-cell chronic lymphocytic leukemia

Data type

boolean

Alias
UMLS CUI [1]
C0475774
rai stage 0, i, or ii
Description

rai stage

Data type

boolean

Alias
UMLS CUI [1]
C1514715
previously untreated
Description

previously untreated

Data type

boolean

Alias
UMLS CUI [1]
C0332155
be able to watch and wait for approximately 8 months following submission of blood (or tissue) while id-klh is being manufactured
Description

waiting ability

Data type

boolean

Alias
UMLS CUI [1,1]
C0849176
UMLS CUI [1,2]
C0085732
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
anti-leukemia treatment prior to beginning immunization
Description

leukemia treatment

Data type

boolean

Alias
UMLS CUI [1,1]
C0023418
UMLS CUI [1,2]
C0087111
anti-leukemia treatment other than id-klh during immunizations
Description

other leukemia treatment

Data type

boolean

Alias
UMLS CUI [1,1]
C0023418
UMLS CUI [1,2]
C0087111
prior malignancy (excluding basal cell carcinoma and cervical carcinoma in situ)
Description

prior malignancy

Data type

boolean

Alias
UMLS CUI [1]
C0006826
pregnant or lactating
Description

pregnancy, lactation

Data type

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
patients with known autoimmune disease (including previously treated autoimmune hemolytic anemia or immune thrombocytopenia)
Description

autoimmune diseases

Data type

boolean

Alias
UMLS CUI [1]
C0004364
participation in any other clinical trial in which an investigational agent is administered
Description

other clinical trial

Data type

boolean

Alias
UMLS CUI [1]
C2348568

Similar models

Eligibility B-Cell Chronic Lymphocytic Leukemia NCT00302861

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
written informed consent
Item
have signed a written informed consent
boolean
C0021430 (UMLS CUI [1])
b-cell chronic lymphocytic leukemia
Item
b-cll diagnosis
boolean
C0475774 (UMLS CUI [1])
rai stage
Item
rai stage 0, i, or ii
boolean
C1514715 (UMLS CUI [1])
previously untreated
Item
previously untreated
boolean
C0332155 (UMLS CUI [1])
waiting ability
Item
be able to watch and wait for approximately 8 months following submission of blood (or tissue) while id-klh is being manufactured
boolean
C0849176 (UMLS CUI [1,1])
C0085732 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
leukemia treatment
Item
anti-leukemia treatment prior to beginning immunization
boolean
C0023418 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
other leukemia treatment
Item
anti-leukemia treatment other than id-klh during immunizations
boolean
C0023418 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
prior malignancy
Item
prior malignancy (excluding basal cell carcinoma and cervical carcinoma in situ)
boolean
C0006826 (UMLS CUI [1])
pregnancy, lactation
Item
pregnant or lactating
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
autoimmune diseases
Item
patients with known autoimmune disease (including previously treated autoimmune hemolytic anemia or immune thrombocytopenia)
boolean
C0004364 (UMLS CUI [1])
other clinical trial
Item
participation in any other clinical trial in which an investigational agent is administered
boolean
C2348568 (UMLS CUI [1])